British researchers are preparing to deliberately expose dozens of volunteers to coronavirus to learn the lowest possible dose that causes an infection.
The data collected will pave the way for further “challenge trials” — where participants are purposefully infected — that will be used to accelerate vaccine development.
The first trial is expected to begin in January and is expected to involve between 30 and 50 healthy volunteers between the ages of 18 and 30.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).